Breast cancer

Drug Name

• A Mechanistic Model of Drug Resistance in ER-Positive, PIK3CA-Mutant Breast Cancer
• ABRAXANE
• AFINITOR
• ANDROXY
• ARIMIDEX
• AROMASIN
• Bioimpedance Spectroscopy May Identify Lymphedema Earlier
• Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer
• Breastfeeding Duration May Influence Markers of Inflammation and Proliferation in Breast Tissue of Healthy Parous Women
• Can BRCA-Positive Patients With Breast Cancer Safely Become Pregnant?
• CAR-T Therapy Injected Directly Into Chest Cavity Shows Early Promise in Pleural Cancers
• Chemotherapy Could Prime Tumors for PD-1 Blockade
• Clinicians Believe Link Between Breast Pain, Cancer Is Weak
• Could Copy Number Detection Solve the Riddle of EGFR Inhibitors in TNBC?
• ctDNA Makes Progress as an Early Treatment Indicator in Breast Cancer
• Cyclophosphamide
• Cyclophosphamide Injection
• Doxorubicin HCl
• Doxorubicin HCl Solution
• Drug Combo Slows Progression in Advanced Breast Cancer
• Dual Anti-HER2 Neoadjvuant Therapy in HER2-Positive Breast Cancer Should Include Chemotherapy
• Efficacy and Safety of Neoadjuvant T-DM1 vs Docetaxel/Trastuzumab/Pertuzumab in Patients With Operable HER2-Positive Breast Cancer
• Elderly Patients With Breast Cancer and CVD Risk Factors Found More Likely to Visit ER
• ELLENCE
• ESTRACE
• EVISTA
• Extended Letrozole Provides Benefit After Adjuvant Tamoxifen
• FARESTON
• FASLODEX
• FDA: Breast Implants Linked to Cancer Can Still Be Sold in US
• FEMARA
• First-in-Class Treatment Approved for Advanced Breast Cancer
• Fixed-Dose Trastuzumab in Early-Stage HER2-Positive Breast Cancer: Unanswered Questions
• Fluorouracil
• Fluoxymesterone
• GEMZAR
• Genetic Testing Underused in Breast, Ovarian Cancer
• HALAVEN
• HER2 Intratumor Heterogeneity as a Biomarker of Nonresponse to Neoadjuvant Dual HER2-Targeted Therapy in HER2-Positive Breast Cancer
• HERCEPTIN
• HERCEPTIN HYLECTA
• Herceptin Hylecta Approved for the Treatment of HER2-Overexpressing Breast Cancer
• High Baseline Inflammatory Biomarker Levels Linked to Shorter OS in mTNBC
• IBRANCE
• Identifying Breast Cancer Subtypes Associated With Late Recurrence
• Immune Biomarkers as Predictors of Response to Checkpoint Blockade in Breast Cancer
• Improved PFS for Pyrotinib Plus Capecitabine vs Placebo Plus Capecitabine in Trastuzumab-Pretreated Metastatic HER2-Positive Breast Cancer
• INFUGEM
• Intraoperative Lidocaine May Reduce Breast Cancer Surgery-Associated Neuropathic Pain
• IXEMPRA
• KADCYLA
• Kadcyla Approved as Adjuvant Treatment for HER2-Positive Early Breast Cancer
• KISQALI
• KISQALI FEMARA CO-PACK
• Long-Term HannaH Data Support Subcutaneous Trastuzumab for Breast Cancer
• Low-Fat Diet Reduced Risk of Death From Breast Cancer in Randomized Trial
• LYNPARZA TABLETS
• Mammo-Based Deep Learning Model Assesses Breast Cancer Risk
• Margetuximab Improved PFS Compared With Trastuzumab in Pretreated Metastatic HER2-Positive Breast Cancer
• Megestrol Tablets
• Methotrexate for injection
• Methotrexate injection
• NCI-MATCH: No Objective Responses to Palbociclib in Patients With CCND-Amplified Tumors
• Neratinib Improved PFS Compared With Lapatinib in Pretreated HER2-Positive Metastatic Breast Cancer
• NERLYNX
• New Lesions ID’d on Breast MRI During Treatment Likely Benign
• No Link Found Between HRD and Pathologic Response in Triple-Negative Breast Cancer
• OS Benefit of Adding Atezolizumab to Nab-Paclitaxel for Patients With Advanced, PD-L1–Positive Triple-Negative Breast Cancer
• OS Improvement With Addition of CDK4/6 Inhibitor to Endocrine Therapy in Younger Women With Metastatic Breast Cancer
• Pamidronate disodium Injection
• PERJETA
• Personalizing Breast Cancer Tx Could Cut Initial Costs of Care
• Phthalates and Postmenopausal Breast Cancer
• Physicians Unaware of Breast Density Laws, Cancer Risk
• PIQRAY
• PREMARIN
• Prospective Evidence Links Textured Breast Implants to Rare Lymphoma
• Radiotherapy Tied to Lower Recurrence of Early, Hormone-Driven Breast Cancer
• Reducing the Economic Burden of Breast Cancer: Patient-Based Recommendations
• Research Examines Breast Cancer Susceptibility Genes in Hispanic Women and Other Diverse Populations
• Risk Factors for CVD More Common in Postmenopausal Women Who Survived Breast Cancer
• Risk-Based Breast Cancer Screening Guidelines from the American Society of Breast Cancer Surgeons
• SOLTAMOX ORAL SOLUTION
• Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
• Talazoparib in Advanced HER2-Negative Breast Cancer and Other Solid Tumors Lacking BRCA1/2 Mutations
• TALZENNA
• Tamoxifen
• TAXOL
• TAXOTERE
• TECENTRIQ
• TEPADINA
• Test Predicts Benefit of Chemo in ER+, HER2− Breast Cancer
• Testosterone Enanthate
• The Hidden Privilege of Reference Genomes
• The Revival of a Forgotten Cancer Gene Therapy With Off-the-Shelf Potential
• Thiotepa
• Trazimera, a Biosimilar to Herceptin, Gets FDA Approval
• TREXALL
• Triple-Negative Breast Cancer Varies by Birthplace for Black Women
• Tumor Hypoxia and Breast Cancer Risk
• Tumor-Infiltrating Lymphocytes and Prognosis in Early-Stage TNBC
• Two RNA Sequencing Inflammatory Scores as Predictors of Benefit From Pembrolizumab in Advanced Breast Cancer
• TYKERB
• Using Institutional Intervention to Reduce Disparities: Same-Day Breast Biopsy
• VERZENIO
• Vinblastine for injection
• Vinblastine injection
• VITRAKVI
• VITRAKVI ORAL SOLUTION
• XELODA
• ZOLADEX